Karen Carey

The company formerly known as Exhale Therapeutics Inc. has acquired a new name, a new financing and new U.S. rights to a pulmonary hypertension product. (BioWorld Today)

Xcyte Seeking $75M In Second Attempt At Initial Public Offering

Oct. 14, 2003

By Karen Carey

XOMA, Millennium Drop Heart Drug; CAB-2 Product Remains

Oct. 13, 2003

By Karen Carey

ID Biomedical Raising $100M To Advance FluINsure, StreptAvax

Oct. 10, 2003

By Karen Carey

CTI Raises $56M In Series B; Asthma Product To Benefit

Oct. 9, 2003

By Karen Carey

Articles by Karen Carey

Genelabs Rakes In $27.4M For Prestara, Hepatitis C Programs

Advancis IPO Raises $60M; Biotech Firms Wait In Wings

Cardiome Pharma, Fujisawa Enter $68M Cardio Drug Deal

With Two Products In Clinic, GTx Seeking $86.25M In IPO

Immunex, Abgenix Revise Plans To Advance ABX-EGF For Cancer

CoTherix Acquires Schering's U.S. Rights For Ventavis, Raises $55M

Xcyte Seeking $75M In Second Attempt At Initial Public Offering

XOMA, Millennium Drop Heart Drug; CAB-2 Product Remains

ID Biomedical Raising $100M To Advance FluINsure, StreptAvax

CTI Raises $56M In Series B; Asthma Product To Benefit

Today's news in brief

MMP inhibitors divulged in Accure Therapeutics patent

News in brief

Selective CBL-B inhibitor with improved safety profile disclosed

MSD discloses new HCN1/2 blockers